

Abstract # 422730: Molecular Predictors and Immunomodulatory Role of Dual Checkpoint Inhibitor Blockade using Ipilimumab/Nivolumab in Advanced Small Cell Lung Cancer Patients

Chiang, AC¹, Asghari, H², Ashley, K³, Gettinger, S¹, Goldberg, S¹, Herbst, R¹, Vilson, FH¹, Newton, BR¹, Cohenuram, MK¹, Sabbath, KD¹, Talsania, AS¹, Russo, AV¹, Schultz, E², Skrzypczak, S², Kingsford, C², Schalper, KA^{1,3}. ¹Yale University School of Medicine/Yale Cancer Center, New Haven, CT, ²Ocean Genomics; ³ Department of Pathology, Yale School of Medicine

Background:


-Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with poor prognosis. In extensive stage (ES-SCLC) patients, frontline treatment with chemoimmunotherapy shows modest clinical benefit. The biological impact of immunotherapy in SCLC is poorly understood with no clear predictive biomarkers to guide patient selection.

-Recently, molecular subtypes characterized by high expression of transcription factors (Subtypes SCLC-A, SCLC-N, SCLC-P) and an alternative fourth subtype SCLC-Inflammatory (SCLC-I) were used for retrospective stratification of IMpower133 patients treated with platinum doublet alone or with atezolizumab. SCLC-I patients in the Atezo arms derived the most benefit compared to chemotherapy with mOS of 18 mo vs 10 mo (*Gay*, et al, 2021 Cancer Cell).

Methods:

- ES-SCLC patients with relapsed disease were treated with combination nivolumab (nivo) and ipilimumab (ipi) in a single-arm, phase 2 clinical trial (NCT03670056).
- Patients received Nivo 1 mg/kg and ipi 3 mg/kg every 3 weeks for 4 cycles, followed by nivo maintenance until progressive disease (PD) by RECIST 1.1 or treatment-limiting toxicity.
- Biopsies were obtained at baseline, week 4 and progression.
- Whole Exome DNA Sequencing (WES) and RNA-sequencing coupled to Ocean Genomics TxomeAl[®] data analysis pipeline to extract genomic and transcriptomic features were performed on aired tumor and germline samples.
- Gene set enrichment analysis was performed between timepoints by employing differentially expressed genes and Reactome and Panther pathway databases.


Schema:




Results:

Biopsy

(Optional)



-Genomic analysis showed patients with PD on treatment had more deleterious HLA-A gene mutations in baseline samples than those with clinical activity (PR+ SD). patients with different treatment responses, but prominently increased in week 4 biopsies of PD patients – 42% mean increase for PD; 45% decrease for clinical activity



progression vs. week 4. In addition, activation & PD-1 signalling T-cell signatures were enriched in week 4.

- -Baseline tumor mutational burden (TMB) was comparable in baseline samples from

Clinical Data:

- 60% patients had PD
- progression.

Major Takeaways:

- and PD-1 signaling.

Future Directions:

YaleNewHavenHealth **Smilow Cancer Hospital**

Acknowledgements: We would like to thank the patients and families for participating in the clinical trial, Bristol-Myers Squibb for providing resources/funding, Yale Clinical Research Support Laboratory (CRSL), Yale Pathology Specialized Translational Services (STS) CLIA Laboratory, and to Illumina for funding and supporting DNA/RNA sequencing

 22 patients enrolled and received treatment, with 15 evaluable per RECIST 1.1 criteria. • 40% patients demonstrated clinical activity (2 PR, 4 SD)

 Paired biopsies pre- and on-treatment were successfully obtained in 16/22 patients, as well as 3 biopsies at

 Comprehensive clinico-genomic and transcriptomic analysis of prospectively collected paired samples from patients on trial is a useful resource to explore tumor adaptations to treatment and biomarkers.

• Genomic and transcriptomic features associated with treatment sensitivity/resistance to dual checkpoint blockade were identified, including increased local adaptive immune responses such as T-cell activation

• SCLC-A subtype patients demonstrated clinical activity to immunotherapy using dual checkpoint blockade

• Further analysis on this SCLC cohort and independent datasets are required to validate findings and uncover additional characteristics of treatment response/resistance. The potential genomic and transcriptomic biomarkers presented here must be further validated.

OCEAN GENOMICS

CANCER CENTER

A Comprehensive Cancer Center Designated by the National Cancer Institute

